Background/Objectives:To determine if the results of cytogenetic analyses of choroidal melanoma biopsies after ruthenium-106 plaque brachytherapy (RPB) are affected by this procedure.Methods: A retrospective study was conducted on 368 patients with choroidal melanoma treated with RPB who underwent cytogenetic testing at the Liverpool Ocular Oncology Centre (LOOC) between May 2012 and November 2024. Data on demographics, tumor characteristics, treatment date, biopsy timing (pre- or post-RPB), and cytogenetic results were extracted from the LOOC database. Statistical analysis included descriptive statistics, binary, and multinomial logistic regression to assess associations between biopsy timing and biopsy success rates.Results: Biopsies were performed before RPB in 58.7% (216/368) cases, and post-PBR in 41.3%. Cytomorphological identification and molecular genetic testing were successful in 96.4% and 85.1% cases, respectively. Timing of biopsy, patient demographics, and tumor characteristics did not significantly influence cytogenetic test outcomes. Molecular testing could not be performed on 6.8% (25/368) cases as the DNA was insufficient in these samples. Genetic testing success slightly declined beyond three months post-RPB, though a few cases had delayed biopsy (n = 8). Pre-RPB biopsies more frequently demonstrated monosomy 3, whereas post-RPB biopsies had higher rates of disomy 3 (χ2,p< 0.05).Conclusions: Prognostic biopsies post-RPB provide reliable cytomorphological and molecular genetic results using MLPA or MSA. Test failure is not significantly influenced by biopsy timing, patient or tumor characteristics, biopsy modality, or genetic technique. Insufficient DNA yield remains a key limitation, emphasizing the importance of obtaining adequate tissue samples. Biopsies within three months are preferable to optimize success in molecular testing.
背景/目的：本研究旨在确定钌-106敷贴近距离放射治疗（RPB）后脉络膜黑色素瘤活检的细胞遗传学分析结果是否受该治疗程序影响。方法：对2012年5月至2024年11月期间在利物浦眼肿瘤中心接受RPB治疗并进行细胞遗传学检测的368例脉络膜黑色素瘤患者进行回顾性研究。从LOOC数据库中提取人口统计学特征、肿瘤特征、治疗日期、活检时机（RPB前或后）及细胞遗传学结果等数据。统计分析包括描述性统计、二元及多项逻辑回归，以评估活检时机与活检成功率之间的关联。结果：58.7%（216/368）的病例在RPB前进行活检，41.3%在RPB后进行。细胞形态学鉴定和分子遗传学检测的成功率分别为96.4%和85.1%。活检时机、患者人口统计学特征及肿瘤特征对细胞遗传学检测结果均无显著影响。6.8%（25/368）的病例因样本DNA量不足无法进行分子检测。RPB后超过三个月进行活检时，遗传学检测成功率略有下降，但延迟活检的病例数较少（n=8）。RPB前活检更常显示3号染色体单体性，而RPB后活检中3号染色体二体性的比例更高（χ2检验，p<0.05）。结论：RPB后的预后活检通过MLPA或MSA技术可获得可靠的细胞形态学和分子遗传学结果。检测失败与活检时机、患者或肿瘤特征、活检方式或遗传学技术无显著相关性。DNA产量不足仍是主要限制因素，凸显了获取足够组织样本的重要性。为优化分子检测成功率，建议在RPB后三个月内进行活检。
肿瘤(癌症)患者之家